ClinicalTrials.gg
CompletedNCT00258739Updated Dec 7, 2009

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine and Docetaxel + gemcitabine + carboplatin + radiotherapy in Lung Neoplasms, sponsored by Sanofi. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-07.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 100 studies testing docetaxel in Lung Neoplasms — 1 open to participants now, 3 under way, 1 of them phase 3. Docetaxel · Lung Neoplasms.

Enrollment
15th of 90
140 · median 46
Started
2001
with 8 others
Phase 2
68 of 100
1 open now
Registered
47th of 100
by date
Lead sponsor
5 of 100
Sanofi

Among the 100 studies testing docetaxel in Lung Neoplasms, this one is the 15th largest by enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2001, is one of 68 in phase 2, and was the 47th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

1 of the 100 studies testing docetaxel in Lung Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing docetaxel in Lung Neoplasms, or all of them as a file.
02

Study summary

Primary objective:

  • To classify the 2 study groups, according to the tumoral response.

Secondary objectives:

  • To evaluate the percentage of focused control per year.
  • To calculate the time until progression.
  • To evaluate the safety profile.
03

Conditions studied

  • Lung Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non small cell lung cancer confirmed by histology or by cytology.
  • IIIB stage, except if existing pleural discharge, upper cava vein syndrome or supraclavicular affectation
  • General stage 0-1 at the scale
  • Loss of weight less than 5% in the 3 previous months from diagnose.
  • Pulmonary function and gasometry results: > 30% or 1 l, DLCO (diffusing capacity of the lung for carbon monoxide) > 30%, PCO2 \< 45 mmHg and PO2 > 60 mmHg.
  • Normal medullar function ( > 11 g/dl, total WBC > 1,5 x 10\^9/l, > 100 x 10\^9/l)
  • Appropriate renal and hepatic functions
  • CTScan
  • Anticonceptive method
  • Available laboratory test (maximum 1 month before)

Exclusion criteria

Exclusion criteria:

  • Pleural discharge, upper cava vein syndrome or supraclavicular affectation.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    1

    Concomitant radiotherapy and carboplatin-docetaxel followed by docetaxel-gemcitabine

    Drug: Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine

  • Experimental
    2

    docetaxel-gemcitabine followed by concomitant radiotherapy with carboplatin-docetaxel

    Other: Docetaxel + gemcitabine + carboplatin + radiotherapy

Interventions

  • DrugDocetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine

    Drug pages: Docetaxel · Carboplatin · Gemcitabine

    Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.

  • OtherDocetaxel + gemcitabine + carboplatin + radiotherapy

    Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).

06

What researchers measure

Primary outcomes

  1. Response rate in each arm measured according to RECIST criteria

    Time frame: Throughout the whole study

Secondary outcomes

  1. Percentage of local-regional control within a year

    Time frame: Throughout the first year

  2. Time to progression defined as the period of time elapsed between the randomization date and the progression or death date

    Time frame: Throughout the whole study

  3. Toxicity measured by CALGB criteria and RTOG/EORTC criteria

    Time frame: Throughout the whole study

  4. Global surveillance measured as the period of time elapsed between randomization and death date.

    Time frame: Throughout the whole study duration

07

Study locations

1 site
  • Sanofi-Aventis
    Barcelona, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2001 and a primary completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2005
First posted
Nov 28, 2005
Start
Oct 2001
Primary completionActual
Sep 2007
Last update
Dec 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00258739
Lead sponsor
Sanofi
First posted
Nov 28, 2005
Start date
Oct 2001
Primary completion
Sep 2007
Last update
Dec 7, 2009

Study contacts

José Mª Taboada
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Carboplatin · Gemcitabine

Start the discussion